U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07379489) titled 'Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma' on Jan. 23.
Brief Summary: Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities. The beneficiaries of adjuvant PD-1 inhibitors (aPD-1) and their efficacy across these temporally divergent recurrence patterns remains unestablished.
Study Start Date: Jan. 31
Study Type: OBSERVATIONAL
Condition:
HCC
Adjuvant Therapy
Recurrence
Immune Checkpoint Inhibitor
Intervention:
DRUG: PD-1 Inhibitors
Patients in the a...